Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a
about
HIV treatment-as-prevention research at a crossroadsSystematic review and meta-analysis of community and facility-based HIV testing to address linkage to care gaps in sub-Saharan AfricaReview: [corrected] The changing face of the HIV epidemic in sub-Saharan AfricaChallenges in initiating antiretroviral therapy for all HIV-infected people regardless of CD4 cell countOptimal Treatment Strategies in the Context of 'Treatment for Prevention' against HIV-1 in Resource-Poor SettingsParticipation dynamics in population-based longitudinal HIV surveillance in rural South AfricaAddressing social issues in a universal HIV test and treat intervention trial (ANRS 12249 TasP) in South Africa: methods for appraisal.A universal testing and treatment intervention to improve HIV control: One-year results from intervention communities in Zambia in the HPTN 071 (PopART) cluster-randomised trial.Global HIV epidemiology: A guide for strategies in prevention and care.Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis.What works - reaching universal HIV testing: lessons from HPTN 071 (PopART) trial in ZambiaGlobal response to HIV: treatment as prevention, or treatment for treatment?Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here?The impact of the 2013 WHO antiretroviral therapy guidelines on the feasibility of HIV population prevention trials.Why the proportion of transmission during early-stage HIV infection does not predict the long-term impact of treatment on HIV incidenceTreatment as prevention--where next?A role for health communication in the continuum of HIV care, treatment, and preventionHIV treatment-as-prevention research: taking the right road at the crossroadsCost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis.Vaccine testing. Ebola and beyond.Estimated age and gender profile of individuals missed by a home-based HIV testing and counselling campaign in a Botswana community.Retention in care prior to antiretroviral treatment eligibility in sub-Saharan Africa: a systematic review of the literatureEvaluating respondent-driven sampling as an implementation tool for universal coverage of antiretroviral studies among men who have sex with men living with HIVHigh rates of unplanned interruptions from HIV care early after antiretroviral therapy initiation in NigeriaLong-Range HIV Genotyping Using Viral RNA and Proviral DNA for Analysis of HIV Drug Resistance and HIV Clustering.Progress in Reversing the HIV Epidemic through Intensified Access to Antiretroviral Therapy: Results from a Nationally Representative Population-Based Survey in Kenya, 2012Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria.Potential impact of multiple interventions on HIV incidence in a hyperendemic region in Western Kenya: a modelling study.The incidence of tuberculosis among hiv-positive individuals with high CD4 counts: implications for policyInitiation of antiretroviral therapy at high CD4+ cell counts is associated with positive treatment outcomes.Uptake of Home-Based HIV Testing, Linkage to Care, and Community Attitudes about ART in Rural KwaZulu-Natal, South Africa: Descriptive Results from the First Phase of the ANRS 12249 TasP Cluster-Randomised TrialThe risk of late or advanced presentation of HIV infected patients is still high, associated factors evolve but impact on overall mortality is vanishing over calendar years: results from the Italian MASTER CohortBeyond Risk Compensation: Clusters of Antiretroviral Treatment (ART) Users in Sexual Networks Can Modify the Impact of ART on HIV Incidence.Time to eligibility for antiretroviral therapy in adults with CD4 cell count > 500 cells/μL in rural KwaZulu-Natal, South AfricaCloser to 90-90-90. The cascade of care after 10 years of ART scale-up in rural Malawi: a population studyAccess to HIV care in the context of universal test and treat: challenges within the ANRS 12249 TasP cluster-randomized trial in rural South AfricaThe current status of the use of oral medication to prevent HIV transmission.Changing HIV treatment eligibility under health system constraints in sub-Saharan Africa: investment needs, population health gains, and cost-effectiveness.The Art of HIV Elimination: Past and Present Science.Factors associated with antiretroviral treatment initiation amongst HIV-positive individuals linked to care within a universal test and treat programme: early findings of the ANRS 12249 TasP trial in rural South Africa.
P2860
Q21144591-4A15366F-3E80-46A3-9E94-365B4398FEE9Q26774956-6F63C679-3614-431C-A557-0B0487D065A6Q27022927-9B96F196-5780-4D03-AC84-4C8E25A49009Q27318314-A589DBE3-BF98-4902-B54F-88E2776F343DQ28547109-0C624ED6-DD38-4F84-A780-125341F80027Q30373717-1A61A40E-5925-40E8-B638-513201CFBC73Q30625366-975F0FE0-BAEE-4140-BC9B-3E9D570027BDQ33626374-BD130744-EA7C-41F9-ACDE-30B980B58F30Q33703135-ACA44F32-0295-460B-BDF3-463549420137Q33712438-E4A08D19-4D3E-4D50-B341-C0947D36360CQ33853675-9F5F95B5-16DB-4CE4-83B2-BA7B9B582357Q34077723-C6829FBD-3603-4E2D-A731-C25E61920B3EQ34379806-0329D162-09AA-4061-9529-A3BA46E898C2Q34418077-F291912D-E55A-4F91-9FFD-D6B1832FCD6EQ34526461-C34CC03D-E168-45BE-85E8-A42369E9D3DCQ34718341-FD72FE85-8C7D-40B2-ACB3-5EC94AB01121Q35043096-41DDC068-4692-4FDD-A82F-655B5193FB35Q35164755-DA3EE5FA-8665-49FC-B2E1-C9325B645368Q35262551-C22F4439-76E5-4334-AA8F-464B783608B9Q35532802-C3328E64-97D9-457E-97A2-858DDFA2BAF6Q35668867-4BE1FAAA-7025-4F8D-B9E3-DAE1A0EA0D0DQ35778800-3FA2ED99-DB98-4457-A594-54F4BDD52A09Q35782801-B64E7CCD-EA85-4846-ABEA-04679464160CQ35794525-17D4FAA5-FE61-41E3-AB07-E151BFB46649Q35868716-CF9AF79C-1314-4B43-B794-99868D3D5ECCQ35940953-AEF9B9A1-F8F5-4AD3-B044-8058F8A9FAF3Q35962509-E034AE52-6C7D-4653-90C1-764C66160914Q36003735-FF42B4A4-086D-4E27-B535-AE2940941F0FQ36048661-866DB8EB-471E-48DE-9A38-7EF2306D0FD6Q36070585-FF9E0C02-349C-482D-9B33-C36C239E2B6DQ36098544-11D7CC5F-CC73-4CD3-87F0-420CA4A9F764Q36112063-C6746E88-68EC-460B-90F0-6A49678F2856Q36140719-2B80878D-E296-4185-8FC7-DB3F6999F870Q36380146-8B8E5192-20E9-48CA-89B4-663CF86C13EAQ36596936-3115B300-788C-4387-A47E-B95B743D489BQ36965839-C97CFAFE-8503-43B3-BC21-732A2014E036Q37212913-334B5092-0F58-4A48-92E5-A536E5DD0ED0Q37244536-74FB4653-9F6E-4E90-8666-D340F2259926Q37354106-CA88D0CE-5D58-41FD-942B-9319FA1138E2Q37395475-0B233337-E64E-4AB8-A11E-2C2DD82DFCC7
P2860
Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a
description
article
@en
im Juli 2013 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в липні 2013
@uk
ലേഖനം
@ml
name
Evaluation of the impact of im ...... h Africa: study protocol for a
@en
Evaluation of the impact of im ...... h Africa: study protocol for a
@nl
type
label
Evaluation of the impact of im ...... h Africa: study protocol for a
@en
Evaluation of the impact of im ...... h Africa: study protocol for a
@nl
prefLabel
Evaluation of the impact of im ...... h Africa: study protocol for a
@en
Evaluation of the impact of im ...... h Africa: study protocol for a
@nl
P2093
P2860
P50
P356
P1433
P1476
Evaluation of the impact of im ...... h Africa: study protocol for a
@en
P2093
Brigitte Bazin
Claire Rekacewicz
France Lert
John Imrie
Sylvie Boyer
P2860
P2888
P356
10.1186/1745-6215-14-230
P407
P50
P577
2013-07-23T00:00:00Z
P5875
P6179
1032777175